[{"id":"fcc05899-00b6-44f1-b7d1-45865d2aff67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05044988","created_at":"2021-09-16T15:55:22.889Z","updated_at":"2024-07-02T16:36:24.402Z","phase":"Phase 2","brief_title":"A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer","source_id_and_acronym":"NCT05044988","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10342"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-09-15"}]